Intervet/Schering-Plough receives approval for intramuscular Nuflor Minidose

Intervet/Schering-Plough Animal Health has received European regulatory approval for a new intramuscular administration method for Nuflor Minidose 450 mg/mL.

The florfenicol-containing broad-spectrum antibiotic has been approved via the decentralised procedure in the European Union as a treatment for bovine respiratory disease via this method.

According to the manufacturer, this ruling will offer a flexible new option for veterinarians treating cattle, adding to the existing subcutaneous administration method approved in 2008.

This will increase the usability of a treatment with proven efficacy against one of the most devastating illnesses affecting bovines.

Francis Adriaens, global marketing director for the global ruminants business unit at Intervet/Schering-Plough, said: "Our customers requested the intramuscular claim when Nuflor Minidose was first introduced and we are delighted to be able to recommend this route of administration henceforth."

Earlier this month, the company announced the launch of BacuCheck, a testing system to determine vaccine compliance with its Porcilis PCV treatment.